Opinion|Videos|November 8, 2024
Intracranial Efficacy of Next-Generation ALK-Targeted Therapies
Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.
Advertisement
- All: Please discuss the efficacy of ALK inhibitors in brain metastases.
- REMARK study (Xiong A, et al. 2024. WCLC. OA09.03)
- CROWN trial (Solomon BJ, et al. Lancet Respir Med. 2023)
- ALTA-3 (Yang JC, et al. J Thorac Oncol. 2023)
- ALTA-1L/brigatinib (Camidge DR, et al. J Clin Oncol. 2021)
- Others
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5
































